176 related articles for article (PubMed ID: 29895278)
1. Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients.
Venturelli E; Orenti A; Fabricio ASC; Garrone G; Agresti R; Paolini B; Bonini C; Gion M; Berrino F; Desmedt C; Coradini D; Biganzoli E
BMC Cancer; 2018 Jun; 18(1):651. PubMed ID: 29895278
[TBL] [Abstract][Full Text] [Related]
2. Recurrence dynamics of breast cancer according to baseline body mass index.
Biganzoli E; Desmedt C; Fornili M; de Azambuja E; Cornez N; Ries F; Closon-Dejardin MT; Kerger J; Focan C; Di Leo A; Nogaret JM; Sotiriou C; Piccart M; Demicheli R
Eur J Cancer; 2017 Dec; 87():10-20. PubMed ID: 29096156
[TBL] [Abstract][Full Text] [Related]
3. Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials.
Neuhouser ML; Aragaki AK; Prentice RL; Manson JE; Chlebowski R; Carty CL; Ochs-Balcom HM; Thomson CA; Caan BJ; Tinker LF; Urrutia RP; Knudtson J; Anderson GL
JAMA Oncol; 2015 Aug; 1(5):611-21. PubMed ID: 26182172
[TBL] [Abstract][Full Text] [Related]
4. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study.
Ritte R; Lukanova A; Berrino F; Dossus L; Tjønneland A; Olsen A; Overvad TF; Overvad K; Clavel-Chapelon F; Fournier A; Fagherazzi G; Rohrmann S; Teucher B; Boeing H; Aleksandrova K; Trichopoulou A; Lagiou P; Trichopoulos D; Palli D; Sieri S; Panico S; Tumino R; Vineis P; Quirós JR; Buckland G; Sánchez MJ; Amiano P; Chirlaque MD; Ardanaz E; Sund M; Lenner P; Bueno-de-Mesquita B; van Gils CH; Peeters PH; Krum-Hansen S; Gram IT; Lund E; Khaw KT; Wareham N; Allen NE; Key TJ; Romieu I; Rinaldi S; Siddiq A; Cox D; Riboli E; Kaaks R
Breast Cancer Res; 2012 May; 14(3):R76. PubMed ID: 22583394
[TBL] [Abstract][Full Text] [Related]
5. Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers.
Farhat GN; Cummings SR; Chlebowski RT; Parimi N; Cauley JA; Rohan TE; Huang AJ; Vitolins M; Hubbell FA; Manson JE; Cochrane BB; Lane DS; Lee JS
J Natl Cancer Inst; 2011 Apr; 103(7):562-70. PubMed ID: 21330633
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of testosterone and SHBG in association with body mass index improve the predictive capability of consolidate tumor biomarkers in pre- and postmenopausal breast cancer patients.
Coradini D; Orenti A; Venturelli E; Cavalleri A; Biganzoli E; Oriana S
Jpn J Clin Oncol; 2018 Apr; 48(4):308-316. PubMed ID: 29474646
[TBL] [Abstract][Full Text] [Related]
7. Testosterone and biological characteristics of breast cancers in postmenopausal women.
Secreto G; Venturelli E; Meneghini E; Greco M; Ferraris C; Gion M; Zancan M; Fabricio AS; Berrino F; Cavalleri A; Micheli A
Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):2942-8. PubMed ID: 19843675
[TBL] [Abstract][Full Text] [Related]
8. Association of Body Fat and Risk of Breast Cancer in Postmenopausal Women With Normal Body Mass Index: A Secondary Analysis of a Randomized Clinical Trial and Observational Study.
Iyengar NM; Arthur R; Manson JE; Chlebowski RT; Kroenke CH; Peterson L; Cheng TD; Feliciano EC; Lane D; Luo J; Nassir R; Pan K; Wassertheil-Smoller S; Kamensky V; Rohan TE; Dannenberg AJ
JAMA Oncol; 2019 Feb; 5(2):155-163. PubMed ID: 30520976
[TBL] [Abstract][Full Text] [Related]
9. Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer.
Dignam JJ; Wieand K; Johnson KA; Raich P; Anderson SJ; Somkin C; Wickerham DL
Breast Cancer Res Treat; 2006 Jun; 97(3):245-54. PubMed ID: 16331345
[TBL] [Abstract][Full Text] [Related]
10. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.
Ewertz M; Gray KP; Regan MM; Ejlertsen B; Price KN; Thürlimann B; Bonnefoi H; Forbes JF; Paridaens RJ; Rabaglio M; Gelber RD; Colleoni M; Láng I; Smith IE; Coates AS; Goldhirsch A; Mouridsen HT
J Clin Oncol; 2012 Nov; 30(32):3967-75. PubMed ID: 23045588
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
[TBL] [Abstract][Full Text] [Related]
12. Adiposity and sex hormones in postmenopausal breast cancer survivors.
McTiernan A; Rajan KB; Tworoger SS; Irwin M; Bernstein L; Baumgartner R; Gilliland F; Stanczyk FZ; Yasui Y; Ballard-Barbash R
J Clin Oncol; 2003 May; 21(10):1961-6. PubMed ID: 12743149
[TBL] [Abstract][Full Text] [Related]
13. Adiposity and estrogen receptor-positive, postmenopausal breast cancer risk: Quantification of the mediating effects of fasting insulin and free estradiol.
Dashti SG; Simpson JA; Karahalios A; Viallon V; Moreno-Betancur M; Gurrin LC; MacInnis RJ; Lynch BM; Baglietto L; Morris HA; Gunter MJ; Ferrari P; Milne RL; Giles GG; English DR
Int J Cancer; 2020 Mar; 146(6):1541-1552. PubMed ID: 31187481
[TBL] [Abstract][Full Text] [Related]
14. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
Regan MM; Neven P; Giobbie-Hurder A; Goldhirsch A; Ejlertsen B; Mauriac L; Forbes JF; Smith I; Láng I; Wardley A; Rabaglio M; Price KN; Gelber RD; Coates AS; Thürlimann B; ;
Lancet Oncol; 2011 Nov; 12(12):1101-8. PubMed ID: 22018631
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.
Kensler KH; Regan MM; Heng YJ; Baker GM; Pyle ME; Schnitt SJ; Hazra A; Kammler R; Thürlimann B; Colleoni M; Viale G; Brown M; Tamimi RM
Breast Cancer Res; 2019 Feb; 21(1):30. PubMed ID: 30795773
[TBL] [Abstract][Full Text] [Related]
16. Pre-Menopausal Women With Breast Cancers Having High AR/ER Ratios in the Context of Higher Circulating Testosterone Tend to Have Poorer Outcomes.
Rajarajan S; Korlimarla A; Alexander A; Anupama CE; Ramesh R; Srinath BS; Sridhar TS; Prabhu JS
Front Endocrinol (Lausanne); 2021; 12():679756. PubMed ID: 34234742
[TBL] [Abstract][Full Text] [Related]
17. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
Cantini L; Pistelli M; Merloni F; Fontana A; Bertolini I; De Angelis C; Bastianelli L; Della Mora A; Santinelli A; Savini A; Maccaroni E; Diodati L; Falcone A; Berardi R
Clin Breast Cancer; 2020 Feb; 20(1):e89-e98. PubMed ID: 31378534
[TBL] [Abstract][Full Text] [Related]
18. The association between metabolic health, obesity phenotype and the risk of breast cancer.
Park YM; White AJ; Nichols HB; O'Brien KM; Weinberg CR; Sandler DP
Int J Cancer; 2017 Jun; 140(12):2657-2666. PubMed ID: 28268252
[TBL] [Abstract][Full Text] [Related]
19. Nodal ratio of positive to excised nodes, but not number of positive lymph nodes is better to predict group to avoid chemotherapy among postmenopausal ER-positive, lymph node-positive T1-T2 breast cancer patients.
Jia XQ; Hong Q; Cheng JY; Li JW; Wang YJ; Mo M; Shao ZM; Shen ZZ; Liu GY
J Cancer Res Ther; 2015; 11(4):740-5. PubMed ID: 26881511
[TBL] [Abstract][Full Text] [Related]
20. Lifetime body size and estrogen-receptor-positive breast cancer risk in the California Teachers Study cohort.
Horn-Ross PL; Canchola AJ; Bernstein L; Neuhausen SL; Nelson DO; Reynolds P
Breast Cancer Res; 2016 Dec; 18(1):132. PubMed ID: 28003027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
